Abstract
Arsenic trioxide ($As_2O_3$) and the proteasome inhibitor bortezomib (BTZ) have been used successfully to treat acute promyelocytic leukemia and multiple myeloma. In this study, interactions between $As_2O_3$ and BTZ were examined in imatinib-resistant Bcr/Abl+ (K562r) cells. Co-treatment with subtoxic concentrations of $As_2O_3$ (2 µM) and BTZ (24 nM) resulted in a synergistic enhancement in growth inhibition and apoptosis. These events were associated with activation of protein kinase Cδ, poly ADP-ribose polymerase cleavage, and caspase-3 activation, along with downregulation of Bcr/Abl mRNA and protein expression levels. These findings suggest that BTZ and $As_2O_3$ act synergistically to induce apoptosis in K562r cells, offering a potential combinatory treatment for chronic myeloid leukemia.
Introduction
Chronic Myelogenous Leukemia (CML) is driven by the Bcr/Abl fusion protein, a constitutively active tyrosine kinase that promotes cell survival and proliferation. While imatinib mesylate (Gleevec) revolutionized CML treatment, many patients develop resistance, often by maintaining Bcr/Abl signaling despite inhibition. This study investigates whether a combination of two established anticancer agents—arsenic trioxide and bortezomib—can overcome this resistance by synergistically targeting the Bcr/Abl pathway.
Methods
The researchers utilized K562 (imatinib-sensitive) and K562r (imatinib-resistant) human CML cell lines. Cell viability was measured using CCK-8 assays, while apoptosis was quantified via Annexin V staining and flow cytometry. Molecular mechanisms were explored through Western blotting for Bcr/Abl, cleaved Caspase-3, PARP, and PKCδ. Additionally, qPCR was used to measure Bcr/Abl mRNA levels, and fluorescent probes were employed to detect changes in Reactive Oxygen Species (ROS).
Results
Synergistic Efficacy at Subtoxic Doses
A critical finding of the study is that $As_2O_3$ and BTZ exhibit potent synergy at low, clinically achievable doses. When used individually at subtoxic levels (2 µM $As_2O_3$ and 24 nM BTZ), the drugs had minimal effect on K562r cells. However, their combination resulted in a dramatic increase in both growth inhibition and the induction of programmed cell death.
Molecular Mechanism of Action
Unlike imatinib, which primarily inhibits Bcr/Abl kinase activity, the $As_2O_3$/BTZ combination was found to downregulate the expression of Bcr/Abl at both the mRNA and protein levels. This depletion of the survival-driving oncoprotein was accompanied by the activation of the apoptotic machinery, including the cleavage of PARP and Caspase-3, and the activation of PKCδ. Interestingly, ROS levels were downregulated during the combination treatment, suggesting a unique disruption of Bcr/Abl-mediated survival signaling.
Discussion
This study demonstrates that the synergistic interaction between $As_2O_3$ and BTZ can effectively overcome imatinib resistance in CML cells. By reducing the total abundance of the Bcr/Abl protein and activating internal apoptotic pathways, this dual-agent approach offers a promising therapeutic strategy. These results provide a strong rationale for further in vivo studies and potential clinical evaluation of this combination for patients with multi-drug resistant CML.
Summary updated